Shanghai Vitalgen BioPharma Co., Ltd. (hereinafter referred to as "Vitalgen" or the "Company") recently announced that VGN-R09b, its independently developed gene therapy product for the treatment of Aromatic L-Amino Acid Decarboxylase Deficiency (AADCD), has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). This marks the second FDA designation received by VGN-R09b within a short period, following its previous Rare Pediatric Disease Designation (RPDD). It represents another key regulatory endorsement in the global development process of VGN-R09b for the AADCD indication.
Orphan Drug Designation (ODD) is a significant incentive program established by the FDA to encourage the development of innovative therapies for rare diseases (affecting fewer than 200,000 people in the United States). Products granted ODD are eligible for various benefits, including seven years of market exclusivity in the U.S. upon approval, tax credits for qualified clinical trial expenses, waiver of Biologics License Application (BLA) fees, and more frequent regulatory guidance from the FDA during the development process. These incentives are designed to significantly reduce development costs and risks, thereby accelerating the drug approval process.
Dr. Zhao Xiaoping, CEO of the company, stated, "VGN-R09b receiving two consecutive FDA designations for the rare pediatric disease indication AADCD is a direct recognition of its clinical value and our global development strategy. We will fully leverage the policy support provided by ODD to efficiently advance its development in the United States, aiming to bring this potentially best-in-class therapy to children in need worldwide as soon as possible."
About AADCD
AADCD is an autosomal recessive inherited neurometabolic disorder caused by pathogenic mutations in the DDC gene, leading to severe deficiencies in the synthesis of key neurotransmitters such as dopamine and serotonin. Affected infants present with severe motor dysfunction, autonomic nervous system disturbances, and intellectual developmental delay. Most fail to achieve motor developmental milestones such as head control, sitting independently, and walking. They face a high risk of mortality during infancy and early childhood, and their quality of life is severely impacted. Currently, there is no effective curative therapy for this disease in China. Conventional treatments can only partially alleviate symptoms and cannot repair the underlying neurological deficits, with particularly limited effects in severely affected patients.
About VGN-R09b
VGN-R09b is a gene therapy product based on a recombinant adeno-associated virus (rAAV) vector. Administered via a one-time intracerebral injection, it is designed to precisely deliver the therapeutic gene to treat the disease at its source. In China, the product has received clinical trial approval from the National Medical Products Administration (NMPA) for the treatment of Aromatic L-Amino Acid Decarboxylase Deficiency (AADCD) and Idiopathic Parkinson's Disease (PD). Specifically, the AADCD indication was officially included in the Breakthrough Therapy Designation list in November 2025. In the United States, the FDA approved the clinical trial of VGN-R09b for Idiopathic PD in July 2024, and it received Fast Track Designation (FTD) in June 2025. In November of the same year, the therapy for AADCD was granted Rare Pediatric Disease Designation (RPDD) by the FDA. Relevant registrational clinical studies are currently being actively advanced.